His primary areas of investigation include Leukemia, Cancer research, Genetics, Mutation and Internal medicine. His Leukemia research is under the purview of Immunology. His Cancer research study integrates concerns from other disciplines, such as Epigenetics, Regulation of gene expression, microRNA and GATA1.
His studies in Mutation integrate themes in fields like Embryonic stem cell, Xenopus, Anatomy, Molecular biology and Acute lymphocytic leukemia. His research integrates issues of Oncology and Locus in his study of Internal medicine. Shai Izraeli interconnects Chromosome breakage and Gene rearrangement in the investigation of issues within Acute leukemia.
His primary areas of study are Cancer research, Leukemia, Immunology, Internal medicine and Genetics. His studies deal with areas such as Haematopoiesis, STAT5, Acute lymphocytic leukemia and B cell as well as Cancer research. His specific area of interest is Leukemia, where Shai Izraeli studies Acute leukemia.
His Immunology study combines topics in areas such as Down syndrome and Somatic cell. His Internal medicine study incorporates themes from Gastroenterology and Oncology. His Gene study combines topics from a wide range of disciplines, such as Molecular biology and Cell biology.
Shai Izraeli mostly deals with Leukemia, Cancer research, Internal medicine, Haematopoiesis and Immunology. He is studying Acute leukemia, which is a component of Leukemia. His Cancer research research is multidisciplinary, incorporating perspectives in Cancer cell, B cell, STAT5, Stem cell and Kinase.
Shai Izraeli combines subjects such as Molecular genetics and Oncology with his study of Internal medicine. His Haematopoiesis research incorporates elements of Progenitor cell and Germline mutation. His study in Immunology is interdisciplinary in nature, drawing from both Down syndrome and Somatic cell.
Leukemia, Cancer research, Genetics, Immunology and Mutation are his primary areas of study. He is interested in Acute leukemia, which is a field of Leukemia. The various areas that Shai Izraeli examines in his Cancer research study include Cancer cell, Cancer genome and Gene mutation.
His Genetics research is multidisciplinary, relying on both Computational biology and Tumor cells. The study incorporates disciplines such as Down syndrome, Disease and Toxicity in addition to Immunology. His research in the fields of Missense mutation overlaps with other disciplines such as Glucosamine.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
Ching Hon Pui;Jun J. Yang;Stephen P. Hunger;Rob Pieters.
Journal of Clinical Oncology (2015)
The MLL recombinome of acute leukemias in 2013
C. Meyer;J. Hofmann;T. Burmeister;D. Gröger.
Diagnostic Assay Based on hsa-miR-205 Expression Distinguishes Squamous From Nonsquamous Non–Small-Cell Lung Carcinoma
Danit Lebanony;Hila Benjamin;Shlomit Gilad;Meital Ezagouri.
Journal of Clinical Oncology (2009)
New insights to the MLL recombinome of acute leukemias
C. Meyer;E. Kowarz;J. Hofmann;A. Renneville.
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome
Dani Bercovich;Ithamar Ganmore;Linda M. Scott;Gilad Wainreb.
The Lancet (2008)
Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias
Chen Shochat;Noa Tal;Noa Tal;Obul R. Bandapalli;Obul R. Bandapalli;Chiara Palmi.
Journal of Experimental Medicine (2011)
Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.
Liat Rainis;Dan Bercovich;Sabine Strehl;Andrea Teigler-Schlegel.
The landscape of somatic mutations in Down syndrome-related myeloid disorders
Kenichi Yoshida;Tsutomu Toki;Yusuke Okuno;Rika Kanezaki.
Nature Genetics (2013)
The MLL recombinome of acute leukemias in 2017
C Meyer;T Burmeister;D Gröger;G Tsaur.
Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol.
Gunnar Cario;Martin Zimmermann;Renja Romey;Stefan Gesk.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: